MicroRNA-532 exerts oncogenic functions in t(4;14) multiple myeloma by targeting CAMK2N1

Tumor-suppressive microRNA-452 inhibits migration and invasion of breast cancer cells by directly targeting RAB11A

(2017) Wanjun Li et al.   Oncology Letters

The bantam microRNA acts through Numb to exert cell growth control and feedback regulation of Notch in tumor-forming stem cells in the Drosophila brain

(2017) Yen-Chi Wu et al.   PLoS Genetics

MicroRNA-532 and microRNA-3064 inhibit cell proliferation and invasion by acting as direct regulators of human telomerase reverse transcriptase in ovarian cancer

(2017) Lin Bai et al.   PLoS One

Patient population with multiple myeloma and transitions across different lines of therapy in the USA: an epidemiologic model

(2016) Javier Cid Ruzafa et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Treatment options for relapsed and refractory multiple myeloma

(2015) A. K. Nooka et al.   BLOOD

miRNA-532-5p functions as an oncogenic microRNA in human gastric cancer by directly targeting RUNX3

(2015) Xia Xu et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

(2015) Sagar Lonial et al.   NEW ENGLAND JOURNAL OF MEDICINE

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

(2015) A. Keith Stewart et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

(2015) Henk M. Lokhorst et al.   NEW ENGLAND JOURNAL OF MEDICINE

MicroRNA Expression Profiling in Clear Cell Renal Cell Carcinoma: Identification and Functional Validation of Key miRNAs

(2015) Haowei He et al.   PLoS One

CAMK2N1 inhibits prostate cancer progression through androgen receptor-dependent signaling

(2015) Tao Wang et al.   Oncotarget

Current treatment landscape for relapsed and/or refractory multiple myeloma

(2014) Meletios A. Dimopoulos et al.   Nature Reviews Clinical Oncology

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

(2013) Jesus San Miguel et al.   LANCET ONCOLOGY

A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial

(2011) K D Boyd et al.   LEUKEMIA

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling

(2010) N C Gutiérrez et al.   LEUKEMIA

High-risk myeloma is associated with global elevation of miRNAs and overexpression ofEIF2C2/AGO2

(2010) Yiming Zhou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma

(2009) M. Lionetti et al.   BLOOD

Regulation of RUNX3 Tumor Suppressor Gene Expression in Cutaneous Melanoma

(2009) M. Kitago et al.   CLINICAL CANCER RESEARCH

Causes and consequences of microRNA dysregulation in cancer

(2009) Carlo M. Croce   NATURE REVIEWS GENETICS

MicroRNA Signature Predicts Survival and Relapse in Lung Cancer

(2008) Sung-Liang Yu et al.   CANCER CELL